Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | STK4 | Q13043 | 1/20 | 0.33 |
| ▸ | STK3 | Q13188 | 1/20 | 0.33 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.33 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.33 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129057 | 0.85 | AURKA (0.39) | CDK2SYKAKT1TGFBR1GSK3A | |
| SCHEMBL16129099 | 0.78 | KDR (0.37) | CDK4CDK2SYKMAPK14AKT1 | |
| SCHEMBL16129100 | 0.78 | MAPK14 (0.35) | SYKMAPK14CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL18386919 | 0.76 | APP (0.40) | CDK4CDK2SYKMAPK14CYP3A4 | |
| SCHEMBL5402771 | 0.76 | RAB9A (0.44) | CDK4CDK2SYKMAPK14CCNE1 | |
| SCHEMBL5388892 | 0.76 | MAPK14 (0.46) | CDK4CDK2SYKMAPK14HSD17B10 | |
| SCHEMBL658219 | 0.76 | CDK4 (0.47) | CDK4CDK2SYKMAPK14CYP1A2 | |
| SCHEMBL5261001 | 0.73 | CDK4 (0.54) | CDK4CDK2SYKMAPK14CCNE1 | |
| SCHEMBL7767558 | 0.73 | CDK4 (0.42) | CDK4CDK2KDM4ENPC1RAB9A | |
| SCHEMBL3203509 | 0.69 | ROCK1 (0.46) | CDK2SYKAKT1TGFBR1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2014151871-A9 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014151871-A2 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | CDK4 488/4885CDK2 147/4885PTGS2 1431/4885 |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | CDK4 459/4885CDK2 132/4885PTGS2 1234/4885 |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | CDK4 488/4885CDK2 147/4885PTGS2 1431/4885 |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | ALK, JAK2, JAK1 | CDK4 488/4885CDK2 147/4885PTGS2 1431/4885 |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | ALK, JAK1, JAK2 | CDK4 506/4885CDK2 215/4885PTGS2 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.